aluates Reports

$ 0.0

Automative

Global Postmenopausal Vaginal Atrophy Therapeutics Market Research Report 2025

Published Date: March 2025

Report Code: QYRE-Auto-22U13537

Global Postmenopausal Vaginal Atrophy Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Postmenopausal Vaginal Atrophy Therapeutics Market Research Report 2025

Code: QYRE-Auto-22U13537

Report

March 2025

Pages:75

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

EndoCeutics

Accord Healthcare

Pfizer Inc

Novo Nordisk

Teva Pharmaceuticals

Shionogi

Bionovo

QuatRx Pharmaceutical Company

Bayer

TherapeuticsMD

Postmenopausal Vaginal Atrophy Therapeutics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Postmenopausal Vaginal Atrophy Therapeutics Market

The global market for Postmenopausal Vaginal Atrophy Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Postmenopausal vaginal atrophy (PVA), also referred to as postmenopausal atrophic vaginitis, caused by the vaginal walls" drying, thinning, and inflammation due to reduced estrogen levels. Women with this disorder are more vulnerable to problems of urinary system and chronic infection of vaginal linings. A variety of medications and therapies available in market that focuses on the underlying cause as well as the symptoms of the condition. These therapies also helps women to improve their quality of life.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Postmenopausal Vaginal Atrophy Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Postmenopausal Vaginal Atrophy Therapeutics.

The Postmenopausal Vaginal Atrophy Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Postmenopausal Vaginal Atrophy Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Postmenopausal Vaginal Atrophy Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Postmenopausal Vaginal Atrophy Therapeutics Market Report

Report Metric	Details
Report Name	Postmenopausal Vaginal Atrophy Therapeutics Market
CAGR	5%
Segment by Type	Estrogen-based Drugs Non-estrogen-based Drugs
Segment by Application	Hospital Specialist Clinic
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Endoceutics, Accord Healthcare, Pfizer, Novo Nordisk, Teva Pharmaceuticals, Shionogi, Bionovo, QuatRx Pharmaceutical Company, Bayer AG, TherapeuticsMD
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Postmenopausal Vaginal Atrophy Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Postmenopausal Vaginal Atrophy Therapeutics Market report?

Ans: The main players in the Postmenopausal Vaginal Atrophy Therapeutics Market are Endoceutics, Accord Healthcare, Pfizer, Novo Nordisk, Teva Pharmaceuticals, Shionogi, Bionovo, QuatRx Pharmaceutical Company, Bayer AG, TherapeuticsMD

What are the Application segmentation covered in the Postmenopausal Vaginal Atrophy Therapeutics Market report?

Ans: The Applications covered in the Postmenopausal Vaginal Atrophy Therapeutics Market report are Hospital, Specialist Clinic

What are the Type segmentation covered in the Postmenopausal Vaginal Atrophy Therapeutics Market report?

Ans: The Types covered in the Postmenopausal Vaginal Atrophy Therapeutics Market report are Estrogen-based Drugs, Non-estrogen-based Drugs

Recommended Reports

Gynecological Health

Urological Disorders

Hormonal Therapies

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Estrogen-based Drugs

1.2.3 Non-estrogen-based Drugs

1.3 Market by Application

1.3.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Specialist Clinic

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Perspective (2020-2031)

2.2 Global Postmenopausal Vaginal Atrophy Therapeutics Growth Trends by Region

2.2.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Postmenopausal Vaginal Atrophy Therapeutics Market Dynamics

2.3.1 Postmenopausal Vaginal Atrophy Therapeutics Industry Trends

2.3.2 Postmenopausal Vaginal Atrophy Therapeutics Market Drivers

2.3.3 Postmenopausal Vaginal Atrophy Therapeutics Market Challenges

2.3.4 Postmenopausal Vaginal Atrophy Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Postmenopausal Vaginal Atrophy Therapeutics Players by Revenue

3.1.1 Global Top Postmenopausal Vaginal Atrophy Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Postmenopausal Vaginal Atrophy Therapeutics Revenue

3.4 Global Postmenopausal Vaginal Atrophy Therapeutics Market Concentration Ratio

3.4.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Therapeutics Revenue in 2024

3.5 Global Key Players of Postmenopausal Vaginal Atrophy Therapeutics Head office and Area Served

3.6 Global Key Players of Postmenopausal Vaginal Atrophy Therapeutics, Product and Application

3.7 Global Key Players of Postmenopausal Vaginal Atrophy Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Postmenopausal Vaginal Atrophy Therapeutics Breakdown Data by Type

4.1 Global Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Type (2026-2031)

5 Postmenopausal Vaginal Atrophy Therapeutics Breakdown Data by Application

5.1 Global Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size (2020-2031)

6.2 North America Postmenopausal Vaginal Atrophy Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2020-2025)

6.4 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size (2020-2031)

7.2 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2020-2025)

7.4 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size (2020-2031)

9.2 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Endoceutics

11.1.1 Endoceutics Company Details

11.1.2 Endoceutics Business Overview

11.1.3 Endoceutics Postmenopausal Vaginal Atrophy Therapeutics Introduction

11.1.4 Endoceutics Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

11.1.5 Endoceutics Recent Development

11.2 Accord Healthcare

11.2.1 Accord Healthcare Company Details

11.2.2 Accord Healthcare Business Overview

11.2.3 Accord Healthcare Postmenopausal Vaginal Atrophy Therapeutics Introduction

11.2.4 Accord Healthcare Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

11.2.5 Accord Healthcare Recent Development

11.3 Pfizer

11.3.1 Pfizer Company Details

11.3.2 Pfizer Business Overview

11.3.3 Pfizer Postmenopausal Vaginal Atrophy Therapeutics Introduction

11.3.4 Pfizer Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

11.3.5 Pfizer Recent Development

11.4 Novo Nordisk

11.4.1 Novo Nordisk Company Details

11.4.2 Novo Nordisk Business Overview

11.4.3 Novo Nordisk Postmenopausal Vaginal Atrophy Therapeutics Introduction

11.4.4 Novo Nordisk Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

11.4.5 Novo Nordisk Recent Development

11.5 Teva Pharmaceuticals

11.5.1 Teva Pharmaceuticals Company Details

11.5.2 Teva Pharmaceuticals Business Overview

11.5.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy Therapeutics Introduction

11.5.4 Teva Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

11.5.5 Teva Pharmaceuticals Recent Development

11.6 Shionogi

11.6.1 Shionogi Company Details

11.6.2 Shionogi Business Overview

11.6.3 Shionogi Postmenopausal Vaginal Atrophy Therapeutics Introduction

11.6.4 Shionogi Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

11.6.5 Shionogi Recent Development

11.7 Bionovo

11.7.1 Bionovo Company Details

11.7.2 Bionovo Business Overview

11.7.3 Bionovo Postmenopausal Vaginal Atrophy Therapeutics Introduction

11.7.4 Bionovo Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

11.7.5 Bionovo Recent Development

11.8 QuatRx Pharmaceutical Company

11.8.1 QuatRx Pharmaceutical Company Company Details

11.8.2 QuatRx Pharmaceutical Company Business Overview

11.8.3 QuatRx Pharmaceutical Company Postmenopausal Vaginal Atrophy Therapeutics Introduction

11.8.4 QuatRx Pharmaceutical Company Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

11.8.5 QuatRx Pharmaceutical Company Recent Development

11.9 Bayer AG

11.9.1 Bayer AG Company Details

11.9.2 Bayer AG Business Overview

11.9.3 Bayer AG Postmenopausal Vaginal Atrophy Therapeutics Introduction

11.9.4 Bayer AG Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

11.9.5 Bayer AG Recent Development

11.10 TherapeuticsMD

11.10.1 TherapeuticsMD Company Details

11.10.2 TherapeuticsMD Business Overview

11.10.3 TherapeuticsMD Postmenopausal Vaginal Atrophy Therapeutics Introduction

11.10.4 TherapeuticsMD Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

11.10.5 TherapeuticsMD Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

EndoCeutics

Accord Healthcare

Pfizer Inc

Novo Nordisk

Teva Pharmaceuticals

Shionogi

Bionovo

QuatRx Pharmaceutical Company

Bayer

TherapeuticsMD

List of Tables

Table 1. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Estrogen-based Drugs

Table 3. Key Players of Non-estrogen-based Drugs

Table 4. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Region (2020-2025)

Table 8. Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Region (2026-2031)

Table 10. Postmenopausal Vaginal Atrophy Therapeutics Market Trends

Table 11. Postmenopausal Vaginal Atrophy Therapeutics Market Drivers

Table 12. Postmenopausal Vaginal Atrophy Therapeutics Market Challenges

Table 13. Postmenopausal Vaginal Atrophy Therapeutics Market Restraints

Table 14. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Players (2020-2025)

Table 16. Global Top Postmenopausal Vaginal Atrophy Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Therapeutics as of 2024)

Table 17. Ranking of Global Top Postmenopausal Vaginal Atrophy Therapeutics Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Postmenopausal Vaginal Atrophy Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Postmenopausal Vaginal Atrophy Therapeutics, Headquarters and Area Served

Table 20. Global Key Players of Postmenopausal Vaginal Atrophy Therapeutics, Product and Application

Table 21. Global Key Players of Postmenopausal Vaginal Atrophy Therapeutics, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share by Type (2020-2025)

Table 25. Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share by Type (2026-2031)

Table 27. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share by Application (2020-2025)

Table 29. Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share by Application (2026-2031)

Table 31. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 46. Endoceutics Company Details

Table 47. Endoceutics Business Overview

Table 48. Endoceutics Postmenopausal Vaginal Atrophy Therapeutics Product

Table 49. Endoceutics Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025) & (US$ Million)

Table 50. Endoceutics Recent Development

Table 51. Accord Healthcare Company Details

Table 52. Accord Healthcare Business Overview

Table 53. Accord Healthcare Postmenopausal Vaginal Atrophy Therapeutics Product

Table 54. Accord Healthcare Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025) & (US$ Million)

Table 55. Accord Healthcare Recent Development

Table 56. Pfizer Company Details

Table 57. Pfizer Business Overview

Table 58. Pfizer Postmenopausal Vaginal Atrophy Therapeutics Product

Table 59. Pfizer Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025) & (US$ Million)

Table 60. Pfizer Recent Development

Table 61. Novo Nordisk Company Details

Table 62. Novo Nordisk Business Overview

Table 63. Novo Nordisk Postmenopausal Vaginal Atrophy Therapeutics Product

Table 64. Novo Nordisk Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025) & (US$ Million)

Table 65. Novo Nordisk Recent Development

Table 66. Teva Pharmaceuticals Company Details

Table 67. Teva Pharmaceuticals Business Overview

Table 68. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy Therapeutics Product

Table 69. Teva Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025) & (US$ Million)

Table 70. Teva Pharmaceuticals Recent Development

Table 71. Shionogi Company Details

Table 72. Shionogi Business Overview

Table 73. Shionogi Postmenopausal Vaginal Atrophy Therapeutics Product

Table 74. Shionogi Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025) & (US$ Million)

Table 75. Shionogi Recent Development

Table 76. Bionovo Company Details

Table 77. Bionovo Business Overview

Table 78. Bionovo Postmenopausal Vaginal Atrophy Therapeutics Product

Table 79. Bionovo Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025) & (US$ Million)

Table 80. Bionovo Recent Development

Table 81. QuatRx Pharmaceutical Company Company Details

Table 82. QuatRx Pharmaceutical Company Business Overview

Table 83. QuatRx Pharmaceutical Company Postmenopausal Vaginal Atrophy Therapeutics Product

Table 84. QuatRx Pharmaceutical Company Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025) & (US$ Million)

Table 85. QuatRx Pharmaceutical Company Recent Development

Table 86. Bayer AG Company Details

Table 87. Bayer AG Business Overview

Table 88. Bayer AG Postmenopausal Vaginal Atrophy Therapeutics Product

Table 89. Bayer AG Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025) & (US$ Million)

Table 90. Bayer AG Recent Development

Table 91. TherapeuticsMD Company Details

Table 92. TherapeuticsMD Business Overview

Table 93. TherapeuticsMD Postmenopausal Vaginal Atrophy Therapeutics Product

Table 94. TherapeuticsMD Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025) & (US$ Million)

Table 95. TherapeuticsMD Recent Development

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

Table 99. Authors List of This Report

List of Figures

Figure 1. Postmenopausal Vaginal Atrophy Therapeutics Picture

Figure 2. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Estrogen-based Drugs Features

Figure 5. Non-estrogen-based Drugs Features

Figure 6. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application: 2024 VS 2031

Figure 8. Hospital Case Studies

Figure 9. Specialist Clinic Case Studies

Figure 10. Postmenopausal Vaginal Atrophy Therapeutics Report Years Considered

Figure 11. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 12. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Region: 2024 VS 2031

Figure 14. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Players in 2024

Figure 15. Global Top Postmenopausal Vaginal Atrophy Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Therapeutics as of 2024)

Figure 16. The Top 10 and 5 Players Market Share by Postmenopausal Vaginal Atrophy Therapeutics Revenue in 2024

Figure 17. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 18. North America Postmenopausal Vaginal Atrophy Therapeutics Market Share by Country (2020-2031)

Figure 19. United States Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. Canada Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Share by Country (2020-2031)

Figure 23. Germany Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. France Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. U.K. Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Italy Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Russia Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Nordic Countries Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Share by Region (2020-2031)

Figure 31. China Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Japan Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. South Korea Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Southeast Asia Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. India Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Australia Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Share by Country (2020-2031)

Figure 39. Mexico Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Brazil Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Share by Country (2020-2031)

Figure 43. Turkey Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Saudi Arabia Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. UAE Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Endoceutics Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

Figure 47. Accord Healthcare Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

Figure 48. Pfizer Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

Figure 49. Novo Nordisk Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

Figure 50. Teva Pharmaceuticals Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

Figure 51. Shionogi Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

Figure 52. Bionovo Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

Figure 53. QuatRx Pharmaceutical Company Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

Figure 54. Bayer AG Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

Figure 55. TherapeuticsMD Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2020-2025)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

Figure 58. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Vaginal Rejuvenation Market Research Report 2024

Vaginal Antifungal Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Vaginitis Therapeutics Market Insights Forecast to 2030

Drugs for Vaginal Fungal Infections Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Atrophic Vaginitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Vaginal Fungi Infections Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Bacterial Vaginosis Therapeutics Market Insights Forecast to 2030

Acute Vulvovaginal Candidiasis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Vulvovaginal Rejuvenation Laser Market Research Report 2024

Global Bacterial Vaginosis Drug Market Insights Forecast to 2030

Global Postmenopausal Vaginal Atrophy Drugs Market Insights Forecast to 2030

Global Postmenopausal Vaginal Atrophy PVA Therapeutics Market Insights Forecast to 2030

Postmenopausal Vaginal Atrophy PVA Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Vulvar and Vaginal Atrophy Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Vasomotor Symptoms of Menopause Treatment Market Research Report 2024

Neovaginal Surgery Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Post Menopausal Osteoporosis Drug Market Research Report 2024

Global Female Urinary Incontinence Treatment Market Research Report 2024

Vulvodynia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions